| NCT05116813 | Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy | TERMINATED | PHASE2, PHASE3 | 2021-10-25 | 2022-08-15 | 2022-06-17 |
| NCT05027997 | Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm | COMPLETED | PHASE2 | 2021-10-06 | 2022-11-27 | 2022-10-27 |
| NCT04857359 | Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy | TERMINATED | PHASE2, PHASE3 | 2021-08-06 | 2022-08-15 | 2022-06-17 |
| NCT01336088 | ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease | COMPLETED | PHASE2 | 2011-04 | 2012-02 | 2012-02 |
| NCT00810485 | ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) | COMPLETED | PHASE2 | 2008-12 | | 2009-12 |
| NCT00820105 | ADX10059 Migraine Prevention Study | TERMINATED | PHASE2 | 2008-12 | | 2010-01 |
| NCT00820079 | ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) | COMPLETED | PHASE2 | 2008-12 | | 2009-10 |